Detalhe da pesquisa
1.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Breast Cancer Res Treat
; 199(3): 457-469, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061619
2.
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Invest New Drugs
; 39(2): 509-515, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32984932
3.
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
Invest New Drugs
; 41(3): 391-401, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37043123
4.
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness".
Cell Rep Med
; : 101595, 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38838676
5.
Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer.
Cancers (Basel)
; 15(19)2023 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37835523
6.
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
Clin Cancer Res
; 28(13): 2878-2889, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507014